Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Símbolo desconocido
Fecha:
Ordernar por:
FechaHoraFuenteTítuloSímboloCompañía
25/04/202401:08PR Newswire (US)Homestyler to Recruit First Batch of Global Partners in 20 Countries
25/04/202401:05GlobeNewswire Inc.UPM Interim Report Q1 2024: A positive start to the year, growth investments contributed to earningsTG:RPLUPM Kymmene Oyj
25/04/202401:04Cointelegraph2 on-chain metrics suggest Bitcoin at its ‘best moment to buy’COIN:BTCUSDBitcoin
25/04/202401:00GlobeNewswire Inc.VAALCO Schedules First Quarter 2024 Earnings Release and Conference CallLSE:EGYVaalco Energy Inc.
25/04/202401:00GlobeNewswire Inc.Boussard & Gavaudan Holding Ltd (EUR): Annual Report and Audited Financial StatementsLSE:BGHLBoussard & Gavaudan Holding Limited
25/04/202401:00GlobeNewswire Inc.Boussard & Gavaudan Holding Ltd (EUR): Annual Report and Audited Financial Statements NSMLSE:BGHLBoussard & Gavaudan Holding Limited
25/04/202401:00GlobeNewswire Inc.Boussard & Gavaudan Holding Ltd (GBP): Annual Report and Audited Financial StatementsEU:BGHSBoussard and Gavaudan Holding
25/04/202401:00Business WireACTICOR BIOTECH: Topline Results of ACTISAVE Phase 2/3 Study in Stroke TreatmentEU:ALACTActicor Biotech
25/04/202401:00Business WireAGM Trading Update - April 2024
25/04/202401:00GlobeNewswire Inc.Irish Residential Properties Sub-Fund 1: Form 8.3 - Irish Residential Properties REIT PLC
25/04/202401:00GlobeNewswire Inc.GALISMMO SCA Entité française du groupe Galimmo Real Estate - Information financière au 31 mars 2024EU:GALIMGalimmo
25/04/202401:00Business WireQ1 2024 resultsNASDAQ:AZNAstraZeneca PLC
25/04/202401:00GlobeNewswire Inc.Subsea 7 S.A. Announces First Quarter 2024 ResultsTG:SOCSubsea 7 SA
25/04/202401:00GlobeNewswire Inc.Galantas Report Annual Financial Results for the Year Ended December 31, 2023TSXV:GALGalantas Gold Corporation
25/04/202401:00GlobeNewswire Inc.Hermès International : Chiffre d'affaires du 1er trimestre 2024TG:HMIHermes International
25/04/202401:00GlobeNewswire Inc.Boussard & Gavaudan Holding Ltd (GBP): Annual Report and Audited Financial Statements NSMEU:BGHSBoussard and Gavaudan Holding
25/04/202401:00GlobeNewswire Inc.Verona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate UpdateNASDAQ:VRNAVerona Pharma Plc
25/04/202401:00GlobeNewswire Inc.Sterling to Add Fixed Income Support to Risk & Margin Service
25/04/202401:00Business WireACTICOR BIOTECH : Résultats principaux de l’étude de phase 2/3 ACTISAVE dans le traitement de l’AVCEU:ALACTActicor Biotech
25/04/202401:00PR Newswire (US)Indivior Announces Q1 2024 Financial ResultsNASDAQ:INDVIndivior PLC
25/04/202401:00PR Newswire (US)Environment Agency to use CACI's Cygnum solution to prepare for and respond to flooding and environmental incidents across England
25/04/202401:00PR Newswire (US)ICEYE and Juniper Re, LLC announce multi-year flood and wildfire data collaborationNASDAQ:BRPBRP Group Inc
25/04/202401:00PR Newswire (US)PRISM BioLab, enters into a Joint Research and Licensing Agreement with Ono
25/04/202401:00PR Newswire (US)Aging Life Care Association® Launches "Ask an Aging Life Care Manager" Series to Support Family Caregivers and Solo Agers
25/04/202401:00GlobeNewswire Inc.Hermès International: First Quarter 2024 RevenueTG:HMIHermes International
25/04/202400:58Business WireRyan nommé parmi les Meilleurs lieux de travailMC au Canada pour la 12e année consécutive par Great Place to Work®
25/04/202400:54Business Wireオープンソース・データベースのリーダーPercona、リズ・ワーナーを最高技術責任者に任命
25/04/202400:53PR Newswire (US)Wanhua Chemical Launches Barcelona R&D Center, Unveiling Signified Focus and Commitment in Europe and Beyond
25/04/202400:52Business WireMundipharma erwirbt alle Vermögenswerte und Rechte an REZZAYO® (Rezafungin) und unterstreicht damit sein Engagement für das Management von Infektionskrankheiten und den Therapiebereich Spezialmedizin
25/04/202400:52Business WireMundipharma acquiert tous les actifs et droits liés à REZZAYO® (rézafungine), renforçant ainsi son engagement continu dans la gestion des maladies infectieuses et les soins spécialisés